Clinical trial

SEMA4C as a Relapse Biomarker in Breast Cancer

NCT03663153

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2022-09-01

PhaseN/A

Study timeline

Study start (estimated)2022-09-01Date precision: day

Registry last updated2021-10-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Interventions

SEMA4C high value follow-up groupOTHER

SEMA4C low value follow-up groupOTHER

Sponsors & collaborators

Tongji Hospitallead sponsor

Hubei Cancer Hospitalcollaborator

Qilu Hospital of Shandong Universitycollaborator

Wuhan Central Hospitalcollaborator

Xiangyang Central Hospitalcollaborator

The First People's Hospital of Jingzhoucollaborator

The First Affiliated Hospital with Nanjing Medical Universitycollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03663153 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.